Title: Mathias Uhlèn: Innovator in Breast Cancer Prognostics
Introduction
Mathias Uhlèn is an accomplished inventor based in Stocksund, Sweden. He is currently associated with Atlas Antibodies AB, where he contributes to advancements in medical research. Although he has not yet been granted any patents, his work is significant in the field of breast cancer prognostics.
Latest Patent Applications
Mathias Uhlèn's notable patent application is titled "ANLN PROTEIN AS AN ENDOCRINE TREATMENT PREDICTIVE FACTOR." This invention provides methods, uses, and means for breast cancer prognostics and treatment prediction. The methods include steps such as providing a sample obtained from a breast cancer subject, evaluating the amount of ANLN protein present in the sample, and determining a sample value corresponding to that amount. The sample value is then compared with a reference value. If the sample value is higher than the reference value, it indicates that the subject is unlikely to benefit from endocrine treatment or that their prognosis is worse than the reference prognosis associated with the reference value.
Conclusion
Mathias Uhlèn's contributions to breast cancer research through his innovative patent application highlight his commitment to improving patient outcomes. His work at Atlas Antibodies AB is paving the way for advancements in cancer treatment and prognostics.